MAIA Biotechnology

Yahoo Finance • 2 days ago

MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent

THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced non-small cell lung cancer (NSCLC) CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NY... Full story

Yahoo Finance • 15 days ago

MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today highlighted p... Full story

Yahoo Finance • 21 days ago

MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer

Poster details durability and efficacy of ateganosine (THIO) treatment in non-small cell lung cancer (NSCLC) CHICAGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-... Full story

Yahoo Finance • last month

MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells

CHICAGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that... Full story

Yahoo Finance • 2 months ago

MAIA Biotechnology Reports FDA's Fast Track Designation For Ateganosine

(RTTNews) - MAIA Biotechnology (MAIA) announced that the FDA has granted Fast Track designation for ateganosine for the treatment of non-small cell lung cancer. Ateganosine is currently being evaluated in a Phase 2 THIO-101 clinical trial... Full story

Yahoo Finance • 2 months ago

MAIA Biotechnology's 41% decline validates InvestingPro's overvalued call

When InvestingPro’s Fair Value model flagged MAIA Biotechnology (NYSE:MAIA) as overvalued in April 2024, the clinical-stage biotechnology company was trading at $2.90. Today, the stock trades at $1.69, validating the model’s assessment wit... Full story

Yahoo Finance • 3 months ago

Maia Biotechnology enters stock purchase agreement for up to $587,905 with Prevail Partners

Maia Biotechnology, Inc. (NYSE American:MAIA), a biotechnology company with a market capitalization of $52.7 million, announced it has entered into a stock purchase agreement with Prevail Partners, LLC to issue and sell up to $587,905 of i... Full story

Yahoo Finance • 3 months ago

MAIA Biotechnology appoints HCC experts to scientific advisory board

CHICAGO - MAIA Biotechnology, Inc. (NYSE American:MAIA), a $52.43 million market cap biotechnology company currently trading at $1.73 per share, has appointed two oncologists specializing in hepatocellular carcinoma (HCC) to its Scientific... Full story

Yahoo Finance • 3 months ago

MAIA Biotechnology, Roche sign supply agreement for cancer therapies

MAIA Biotechnology (MAIA) announced its entry into a clinical master supply agreement with Roche (RHHBY) for future studies. The agreement will investigate the combination of MAIA’s telomere-targeting agent ateganosine, sequenced with Roch... Full story

Yahoo Finance • 3 years ago

Sidoti's January Micro-Cap Conference

NEW YORK, NY / ACCESSWIRE / January 17, 2023 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023. The links can a... Full story